SWHR Provides Feedback to ICER on Draft Evidence Report on Treatments for Alzheimer’s Disease

SWHR provided feedback to the Institute for Clinical and Economic Review (ICER) in response to its Draft Evidence Report assessing the comparative clinical effectiveness and value of emerging anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease.

Read the Letter